Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Two groups of patients will be compared: One group of patients with a history of venous thromboembolic disease and one group without. Both groups will be subjected to a walking test and with electrocardiogram measurements and blood tests.
Induced venous thromboembolism is a situation in which venous thromboembolic disease is triggered by an acute event that activates hemostasis: surgery, trauma, infectious or inflammatory outbreak, etc., a situation in which the risk of spontaneous recurrence, in the absence of a new provoking circumstance, is low, leading to the suggestion, not of long-term thromboprophylaxis, but simply the transient prevention of an event when there is a new clinical event likely to activate hemostasis. One such event is acute physical exertion.
Indeed, cohort studies seem to show that regular physical activity is associated with a low incidence of venous thromboembolism. Trained individuals have an endogenous thrombotic potential, assessed by the thrombin TGT test, lower than that of sedentary controls. A 3-month regimen of daily endurance exercise reduces thrombin generation controls and optimizes the fibrinolytic system. Repetitive exercise is accompanied by a depletion of exercise-induced platelet activation. However, several cases of venous thromboembolism have been reported in high-level athletes without usual risk factors and acute high-intensity rowing induces an acute increase in thrombin generation immediately after exercise, which disappears within 16 to 24 hours. The relationship between the level of physical activity and the risk of VTE could be a U-shaped relation, with an increasing risk of event in intense acute practice.
However, no data exists on the hemostatic impact of an acute session of physical activity in patients with a history of venous thromboembolism. Thus, the hypothesis is that exercise-induced response of hemostasis differ in patients with an history of provoked VTE compared to subjects without a history of venous thromboembolism.
This is a proof-of-concept, pathophysiological, single-center, cross-sectional, prospective comparison study of a group of patients with a personal history of induced Venous thromboembolism to a group of sex- and age- and sex-matched controls (+/- 5 years).
- Type of clinical study: Stress test-induced variations in parameters describing the results of the thrombin generation test (Thromboscreen®) in a group of Patients (Cases) will be compared with those obtained in a group of Control subjects (Controls) with a ratio 1:1.
The Patients group comprises 47 patients with a personal history of induced venous thromboembolism, the last event dating back to more than 6 months, whose clinical phenotype did not justify long-term antithrombotic drug prophylaxis.The Control group comprises 47 patients with no personal history of venous thromboembolism and no family history of venous thromboembolism in first-degree relatives.
The study intervention consists of an hour-long walking test and two blood tests in both groups for all participants (Controls and Patients).
- Intra-individual reproducibility will be analyzed in 20 subjects (10 patients and 10 controls) who will take the walking test twice on two separate days.
Patients will be selected during a venous thromboembolism follow-up consultation by a physician from either department (Vascular Medicine Consultation or Biological Hematology and Consultations).Inclusion and non-inclusion criteria will be checked, and the study will be explained to participants (patients and controls).Patients and controls will be systematically asked to take part in the variability analysis on a voluntary basis, until 10 subjects per group have agreed to carry out the second test.
The walking test is performed in the morning, 2 hours after a standard breakfast, on a treadmill. It will be preceded by a clinical examination, a resting 12-lead electrocardiogram and a brachial pressure measurement. After a 3-minute warm-up and "habituation" period (walking speed 2.5 km per hour with no incline), the speed and incline will be gradually increased until a target heart rate close to the theoretical ventilatory threshold, and of the order of 70% of the theoretical maximum value (evaluated by Astrand's formula: 220-age), so as to maintain aerobic exercise conditions of moderate intensity, enabling prolonged effort to be maintained. Blood samples will be taken from each participant whilst at rest, before undergoing the 60-minute walking test, in a sitting position, and just after the exercise test.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group | Active Comparator | Subjects with neither a personal history nor family history of venous thromboembolism in first-degree relatives. |
|
| Patients | Active Comparator | Patients with a personal history of induced venous thromboembolism, the last attack dating back to more than 6 months, whose clinical phenotype did not justify long-term antithrombotic drug prophylaxis |
|
| Individual reproducibility" subgroup: controls | Active Comparator | 10 subjects with neither a personal history nor family history of venous thromboembolism in first-degree relatives who have accepted to re-do the test one week later. |
|
| Individual reproducibility" subgroup: patients | Active Comparator | 10 patients with a history of induced venous thromboembolism, the last attack dating back to more than 6 months, whose clinical phenotype did not justify long-term antithrombotic drug prophylaxis, who have accepted to re-do the test one week later. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 60-minute walking test | Other | Treadmill walking test in the morning, 2 hours after breakfast, following a clinical examination, resting 12-lead electrocardiogram and blood pressure measurement. After a 3-minute warm-up and walking of speed 2.5 km per hour, no incline, the speed and incline are gradually increased to reach a target heart rate close to the theoretical ventilatory threshold, around 70% of the theoretical maximum value (evaluated by Astrand's formula: 220-age), i.e. aerobic conditions of moderate intensity so that prolonged effort can be maintained. Test performed in presence of a physician trained in stress testing. Emergency cart and defibrillator available in the department. Intra-hospital vital emergency protocol in place, with resuscitation teams on standby. The cardiology department, in the same building, can be contacted in the event of a cardiological abnormality during the test or recovery. The test takes 60 minutes, including a 3-minute initial warm-up. |
| Measure | Description | Time Frame |
|---|---|---|
| Thrombin generation dosage before effort in controls | The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM) | Day 0 |
| Thrombin generation dosage before effort in patients | The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM) | Day 0 |
| Thrombin generation dosage after effort in controls | The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM). The difference between measurements before and after effort will be measured in nM.min-1 | Day 0 |
| Thrombin generation dosage after effort in patients | The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM). The difference between measurements before and after effort will be measured in nM.min-1 | Day 0 |
| Thrombin generation dosage before effort in the "Individual reproducibility" subgroup: controls | The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM) | Day 7 |
| Thrombin generation dosage before effort in the "Individual reproducibility" subgroup: patients | The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM) | Day 7 |
| Thrombin generation dosage after effort in the "Individual reproducibility" subgroup: controls |
| Measure | Description | Time Frame |
|---|---|---|
| Distribution in the Control group | Measurements in nM.min-1 will be compared to elicit central tendency, dispersion and heterogeneity in the Control group | Day 0 |
| Distribution in the Patient group |
| Measure | Description | Time Frame |
|---|---|---|
| Age in Controls | Ages will be recorded in years | Day 0 |
| Sex in Controls | Sex will be recorded as Male/Female/Non-binary | Day 0 |
Inclusion Criteria:
Inclusion criteria specific to the Patient Group:
Definition of provoked venous thromboembolism : The clinical criteria used to classify venous thromboembolism as provoked are :
Inclusion criteria specific to the Control Group:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Antonia PEREZ MARTIN, Prof. | Contact | +334 66 68 33 13 | antonia.perez.martin@chu-nimes.fr | |
| Anissa MEGZARI | Contact | +33466684236 | drc@chu-nimes.fr |
| Name | Affiliation | Role |
|---|---|---|
| Antonia PEREZ MARTIN, Prof. | Nîmes University Hospital | Principal Investigator |
| Stéphane FAURE | Nîmes University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nîmes | Recruiting | Nîmes | Occitanie | 30029 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36608393 | Background | Gris JC, Guillotin F, Dos Santos TP, Chea M, Loubet P, Laureillard D, Sotto A, Muller L, Barbar SD, Roger C, Lefrant JY, Jung B, Klouche K, Mura T, Quere I, Perez-Martin A. Prognostic value of an automated thrombin generation assay in COVID-19 patients entering hospital: A multicentric, prospective observational study. Thromb Res. 2023 Feb;222:85-95. doi: 10.1016/j.thromres.2022.12.019. Epub 2023 Jan 2. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054556 | Venous Thromboembolism |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015924 | Blood Pressure Monitors |
| ID | Term |
|---|---|
| D019722 | Sphygmomanometers |
| D019719 | Diagnostic Equipment |
| D004864 | Equipment and Supplies |
Not provided
Not provided
This is a single-center, prospective, cross-sectional, proof-of-concept study,
Not provided
Not provided
Not provided
Not provided
|
|
| Static blood test | Diagnostic Test | 33.3 ml of blood will be taken from each participant whilst at rest, before undergoing the 60-minute walking test |
|
| Post-effort blood test | Diagnostic Test | 33.3 ml of blood will be taken from each participant immediately after undergoing the 60-minute walking test. |
|
| Electrocardiogram | Other | An electrocardiogram will be carried out throughout the exercise period and during the first 30 minutes of recovery. |
|
| Blood pressure monitoring | Other | Blood pressure will be monitored out throughout the exercise period and during the first 30 minutes of recovery. |
|
The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM). The difference between measurements before and after effort will be measured in nM.min-1 |
| Day 7 |
| Thrombin generation dosage after effort in the "Individual reproducibility" subgroup: patients | The amount of thrombomodulin in the blood will be measured in nmol/L with the help of Thromboscreen(TM). The difference between measurements before and after effort will be measured in nM.min-1 | Day 7 |
Measurements in nM.min-1 will be compared to elicit central tendency, dispersion and heterogeneity in the Patient group
| Day 0 |
| Thromboscreen test in Controls in the absence of thrombomodulin : Latency time | Latency time in the absence of thrombomodulin will be measured in seconds in Controls. | Day 0 |
| Thromboscreen test in Controls in the absence of thrombomodulin : Thrombin peak intensity | Thrombin peak intensity in the absence of thrombomodulin will be measured in Controls. | Day 0 |
| Thromboscreen test in Controls in the absence of thrombomodulin : Time-to-peak thrombin | Time-to-peak thrombin in the absence of thrombomodulin will be measured in Controls. | Day 0 |
| Thromboscreen test in Controls in the absence of thrombomodulin : Initial thrombin generation velocity | Initial thrombin generation velocity in the absence of thrombomodulin will be measured in seconds in Controls. | Day 0 |
| Thromboscreen test in Controls in the absence of thrombomodulin : Time to return to baseline | Time to return to baseline in the absence of thrombomodulin will be measured in seconds in Controls. | Day 0 |
| Thromboscreen test in Controls in the presence of thrombomodulin : Latency time | Latency time in the presence of thrombomodulin will be measured in seconds in Controls. | Day 0 |
| Thromboscreen test in Controls in the presence of thrombomodulin : Thrombin peak intensity | Thrombin peak intensity in the presence of thrombomodulin will be measured in Controls. | Day 0 |
| Thromboscreen test in Controls in the presence of thrombomodulin : Time-to-peak thrombin | Time-to-peak thrombin in the presence of thrombomodulin will be measured in Controls. | Day 0 |
| Thromboscreen test in Controls in the presence of thrombomodulin : Initial thrombin generation velocity | Initial thrombin generation velocity in the presence of thrombomodulin will be measured in seconds in Controls. | Day 0 |
| Thromboscreen test in Controls in the presence of thrombomodulin : Time to return to baseline | Time to return to baseline in the presence of thrombomodulin will be measured in seconds in Controls. | Day 0 |
| Thromboscreen test in Patients in the absence of thrombomodulin : Latency time | Latency time in the absence of thrombomodulin will be measured in seconds in Patients. | Day 0 |
| Thromboscreen test in Patients in the absence of thrombomodulin : Thrombin peak intensity | Thrombin peak intensity in the absence of thrombomodulin will be measured in Patients. | Day 0 |
| Thromboscreen test in Patients in the absence of thrombomodulin : Time-to-peak thrombin | Time-to-peak thrombin, initial thrombin generation velocity, time to return to baseline for the thrombin generation test performed in the absence of thrombomodulin will be measured in seconds in Patients. | Day 0 |
| Thromboscreen test in Patients in the absence of thrombomodulin : Initial thrombin generation velocity | Initial thrombin generation velocity in the absence of thrombomodulin will be measured in seconds in Patients. | Day 0 |
| Thromboscreen test in Patients in the absence of thrombomodulin : Time to return to baseline | Time to return to baseline in the absence of thrombomodulin will be measured in seconds in Patients. | Day 0 |
| Thromboscreen test in Patients in the presence of thrombomodulin : Latency time | Latency time in the presence of thrombomodulin will be measured in seconds in Patients. | Day 0 |
| Thromboscreen test in Patients in the presence of thrombomodulin : Thrombin peak intensity | Thrombin peak intensity in the presence of thrombomodulin will be measured in seconds in Patients. | Day 0 |
| Thromboscreen test in Patients in the presence of thrombomodulin : Time-to-peak thrombin | Time-to-peak thrombin in the presence of thrombomodulin be measured in seconds in Patients. | Day 0 |
| Thromboscreen test in Patients in the presence of thrombomodulin : Initial thrombin generation velocity | Initial thrombin generation velocity in the presence of thrombomodulin will be measured in seconds in Patients. | Day 0 |
| Thromboscreen test in Patients in the presence of thrombomodulin : Time to return to baseline | Time to return to baseline in the presence of thrombomodulin will be measured in seconds in Patients. | Day 0 |
| Distribution of other parameters of the Thromboscreen test in Controls | The distribution (central tendency, dispersion, heterogeneity), of the various biological parameters (latency time, thrombin peak intensity, time-to-peak thrombin, initial thrombin generation velocity, time to return to baseline) will be measured in Controls | Day 0 |
| Distribution of other parameters of the Thromboscreen test in Patients | The distribution (central tendency, dispersion, heterogeneity), of the various biological parameters (latency time, thrombin peak intensity, time-to-peak thrombin, initial thrombin generation velocity, time to return to baseline) will be measured in Patients | Day 0 |
| Endogenous Thrombotic Potential in the presence of thrombomodulin in Controls | nM.min | Day 0 |
| Endogenous Thrombotic Potential in the absence of thrombomodulin in Controls | nM.min | Day 0 |
| Endogenous Thrombotic Potential in the presence of thrombomodulin in Patients | nM.min | Day 0 |
| Endogenous Thrombotic Potential in the absence of thrombomodulin in Patients | nM.min | Day 0 |
| Heterogeneity of Endogenous Thrombotic Potential in Controls | Statistical analysis, Cochrane's Q test | Day 0 |
| Heterogeneity of Endogenous Thrombotic Potential in Patients | Statistical analysis, Cochrane's Q test | Day 0 |
| Complete Blood Count in Controls before the walking test: White blood cells | White blood cells will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls before the walking test: White blood cells | White blood cells will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls after the walking test: White blood cells | White blood cells will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls after the walking test: White blood cells | White blood cells will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients before the walking test: White blood cells | White blood cells will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients before the walking test: White blood cells | White blood cells will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients after the walking test: White blood cells | White blood cells will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients after the walking test: White blood cells | White blood cells will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls before the walking test: Red blood cells | Red blood cells will be measured in millions per cubic millimeter | Day 0 |
| Complete Blood Count in Controls before the walking test: Red blood cells | Red blood cells will be measured in millions per cubic millimeter | Day 7 |
| Complete Blood Count in Patients before the walking test: Red blood cells | Red blood cells will be measured in millions per cubic millimeter | Day 0 |
| Complete Blood Count in Patients before the walking test: Red blood cells | Red blood cells will be measured in millions per cubic millimeter | Day 7 |
| Complete Blood Count in Controls after the walking test: Red blood cells | Red blood cells will be measured in millions per cubic millimeter | Day 0 |
| Complete Blood Count in Controls after the walking test: Red blood cells | Red blood cells will be measured in millions per cubic millimeter | Day 7 |
| Complete Blood Count in Patients after the walking test: Red blood cells | Red blood cells will be measured in millions per cubic millimeter | Day 0 |
| Complete Blood Count in Patients after the walking test: Red blood cells | Red blood cells will be measured in millions per cubic millimeter | Day 7 |
| Complete Blood Count in Controls before the walking test:Hemaglobin | Hemaglobin will be measured in g/L | Day 0 |
| Complete Blood Count in Controls before the walking test:Hemaglobin | Hemaglobin will be measured in g/L | Day 7 |
| Complete Blood Count in Patients before the walking test:Hemaglobin | Hemaglobin will be measured in g/L | Day 0 |
| Complete Blood Count in Patients before the walking test:Hemaglobin | Hemaglobin will be measured in g/L | Day 7 |
| Complete Blood Count in Controls after the walking test: Hemaglobin | Hemaglobin will be measured in g/L | Day 0 |
| Complete Blood Count in Controls after the walking test: Hemaglobin | Hemaglobin will be measured in g/L | Day 7 |
| Complete Blood Count in Patients after the walking test: Hemaglobin | Hemaglobin will be measured in g/L | Day 0 |
| Complete Blood Count in Patients after the walking test: Hemaglobin | Hemaglobin will be measured in g/L | Day 7 |
| Complete Blood Count in Controls before the walking test: Hematocrite | Hematrocrite will be measured in L/L | Day 0 |
| Complete Blood Count in Controls before the walking test: Hematocrite | Hematrocrite will be measured in L/L | Day 7 |
| Complete Blood Count in Patients before the walking test: Hematocrite | Hematrocrite will be measured in L/L | Day 0 |
| Complete Blood Count in Patients before the walking test: Hematocrite | Hematrocrite will be measured in L/L | Day 7 |
| Complete Blood Count in Controls after the walking test: Hematocrite | Hematrocrite will be measured in L/L | Day 0 |
| Complete Blood Count in Controls after the walking test: Hematocrite | Hematrocrite will be measured in L/L | Day 7 |
| Complete Blood Count in Patients after the walking test: Hematocrite | Hematrocrite will be measured in L/L | Day 0 |
| Complete Blood Count in Patients after the walking test: Hematocrite | Hematrocrite will be measured in L/L | Day 7 |
| Complete Blood Count in Controls before the walking test: mean corpuscular volume | Mean corpuscular volume will be measured in fL | Day 0 |
| Complete Blood Count in Controls before the walking test: mean corpuscular volume | Mean corpuscular volume will be measured in fL | Day 7 |
| Complete Blood Count in Patients before the walking test: mean corpuscular volume | Mean corpuscular volume will be measured in fL | Day 0 |
| Complete Blood Count in Patients before the walking test: mean corpuscular volume | Mean corpuscular volume will be measured in fL | Day 7 |
| Complete Blood Count in Controls after the walking test: mean corpuscular volume | Mean corpuscular volume will be measured in fL | Day 0 |
| Complete Blood Count in Controls after the walking test: mean corpuscular volume | Mean corpuscular volume will be measured in fL | Day 7 |
| Complete Blood Count in Patients after the walking test: mean corpuscular volume | Mean corpuscular volume will be measured in fL | Day 0 |
| Complete Blood Count in Patients after the walking test: mean corpuscular volume | Mean corpuscular volume will be measured in fL | Day 7 |
| Complete Blood Count in Controls before the walking test: mean corpuscular hemoglobin | Mean Corpuscular Hemoglobin will be measured in pg | Day 0 |
| Complete Blood Count in Controls before the walking test: mean corpuscular hemoglobin | Mean Corpuscular Hemoglobin will be measured in pg | Day 7 |
| Complete Blood Count in Patients before the walking test: mean corpuscular hemoglobin | Mean Corpuscular Hemoglobin will be measured in pg | Day 0 |
| Complete Blood Count in Patients before the walking test: mean corpuscular hemoglobin | Mean Corpuscular Hemoglobin will be measured in pg | Day 7 |
| Complete Blood Count in Controls after the walking test: Mean corpuscular hemoglobin | Mean Corpuscular Hemoglobin will be measured in pg | Day 0 |
| Complete Blood Count in Controls after the walking test: Mean corpuscular hemoglobin | Mean Corpuscular Hemoglobin will be measured in pg | Day 7 |
| Complete Blood Count in Patients after the walking test: Mean corpuscular hemoglobin | Mean Corpuscular Hemoglobin will be measured in pg | Day 0 |
| Complete Blood Count in Patients after the walking test: Mean corpuscular hemoglobin | Mean Corpuscular Hemoglobin will be measured in pg | Day 7 |
| Complete Blood Count in Controls before the walking test: Mean corpuscular hemoglobin concentration | Mean Corpuscular Hemoglobin Concentration will be measured in g/L | Day 0 |
| Complete Blood Count in Controls before the walking test: Mean corpuscular hemoglobin concentration | Mean Corpuscular Hemoglobin Concentration will be measured in g/L | Day 7 |
| Complete Blood Count in Patients before the walking test: Mean corpuscular hemoglobin concentration | Mean Corpuscular Hemoglobin Concentration will be measured in g/L | Day 0 |
| Complete Blood Count in Patients before the walking test: Mean corpuscular hemoglobin concentration | Mean Corpuscular Hemoglobin Concentration will be measured in g/L | Day 7 |
| Complete Blood Count in Controls after the walking test: Mean corpuscular hemoglobin concentration | Mean Corpuscular Hemoglobin Concentration will be measured in g/L | Day 0 |
| Complete Blood Count in Controls after the walking test: Mean corpuscular hemoglobin concentration | Mean Corpuscular Hemoglobin Concentration will be measured in g/L | Day 7 |
| Complete Blood Count in Patients after the walking test: Mean corpuscular hemoglobin concentration | Mean Corpuscular Hemoglobin Concentration will be measured in g/L | Day 0 |
| Complete Blood Count in Patients after the walking test: Mean corpuscular hemoglobin concentration | Mean Corpuscular Hemoglobin Concentration will be measured in g/L | Day 7 |
| Complete Blood Count in Controls before the walking test: red cell distribution width | Red cell distribution width will be measured as % | Day 0 |
| Complete Blood Count in Controls before the walking test: red cell distribution width | Red cell distribution width will be measured as % | Day 7 |
| Complete Blood Count in Patients before the walking test: red cell distribution width | Red cell distribution width will be measured as % | Day 0 |
| Complete Blood Count in Patients before the walking test: red cell distribution width | Red cell distribution width will be measured as % | Day 7 |
| Complete Blood Count in Controls after the walking test: red cell distribution width | Red cell distribution width will be measured as % | Day 0 |
| Complete Blood Count in Controls after the walking test: red cell distribution width | Red cell distribution width will be measured as % | Day 7 |
| Complete Blood Count in Patients after the walking test: red cell distribution width | Red cell distribution width will be measured as % | Day 0 |
| Complete Blood Count in Patients after the walking test: red cell distribution width | Red cell distribution width will be measured as % | Day 7 |
| Complete Blood Count in Controls before the walking test: Platelets | Platelets will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls before the walking test: Platelets | Platelets will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients before the walking test: Platelets | Platelets will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients before the walking test: Platelets | Platelets will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls after the walking test: Platelets | Platelets will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls after the walking test: Platelets | Platelets will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients after the walking test: Platelets | Platelets will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients after the walking test: Platelets | Platelets will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls before the walking test: Neutrophils | Neutrophils will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls before the walking test: Neutrophils | Neutrophils will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients before the walking test: Neutrophils | Neutrophils will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients before the walking test: Neutrophils | Neutrophils will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls after the walking test: Neutrophils | Neutrophils will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls after the walking test: Neutrophils | Neutrophils will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients after the walking test: Neutrophils | Neutrophils will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients after the walking test: Neutrophils | Neutrophils will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls before the walking test: Lymphocytes | Lymphocytes will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls before the walking test: Lymphocytes | Lymphocytes will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients before the walking test: Lymphocytes | Lymphocytes will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients before the walking test: Lymphocytes | Lymphocytes will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls after the walking test: Lymphocytes | Lymphocytes will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls after the walking test: Lymphocytes | Lymphocytes will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients after the walking test: Lymphocytes | Lymphocytes will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients after the walking test: Lymphocytes | Lymphocytes will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls before the walking test: Monocytes | Monocytes will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls before the walking test: Monocytes | Monocytes will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients before the walking test: Monocytes | Monocytes will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients before the walking test: Monocytes | Monocytes will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls after the walking test: Monocytes | Monocytes will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls after the walking test: Monocytes | Monocytes will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients after the walking test: Monocytes | Monocytes will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients after the walking test: Monocytes | Monocytes will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls before the walking test: Eosinophils | Eosinophils will be measured in hundreds/µL | Day 0 |
| Complete Blood Count in Controls before the walking test: Eosinophils | Eosinophils will be measured in hundreds/µL | Day 7 |
| Complete Blood Count in Patients before the walking test: Eosinophils | Eosinophils will be measured in hundreds/µL | Day 0 |
| Complete Blood Count in Patients before the walking test: Eosinophils | Eosinophils will be measured in hundreds/µL | Day 7 |
| Complete Blood Count in Controls after the walking test: Eosinophils | Eosinophils will be measured in hundreds/µL | Day 0 |
| Complete Blood Count in Controls after the walking test: Eosinophils | Eosinophils will be measured in hundreds/µL | Day 7 |
| Complete Blood Count in Patients after the walking test: Eosinophils | Eosinophils will be measured in hundreds/µL | Day 0 |
| Complete Blood Count in Patients after the walking test: Eosinophils | Eosinophils will be measured in hundreds/µL | Day 7 |
| Complete Blood Count in Controls before the walking test: Basophils | Basophils will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls before the walking test: Basophils | Basophils will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients before the walking test: Basophils | Basophils will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients before the walking test: Basophils | Basophils will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Controls after the walking test: Basophils | Basophils will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Controls after the walking test: Basophils | Basophils will be measured in thousands/µL | Day 7 |
| Complete Blood Count in Patients after the walking test: Basophils | Basophils will be measured in thousands/µL | Day 0 |
| Complete Blood Count in Patients after the walking test: Basophils | Basophils will be measured in thousands/µL | Day 7 |
| NETosis markers in Controls before the walking test | Fluorescence signal intensity of neutrophils will be measured on a SYSMEX automat | Day 0 |
| NETosis markers in Controls after the walking test | Fluorescence signal intensity of neutrophils will be measured on a SYSMEX automat | Day 0 |
| NETosis markers in Patients before the walking test | Fluorescence signal intensity of neutrophils will be measured on a SYSMEX automat | Day 7 |
| NETosis markers in Patients after the walking test | Fluorescence signal intensity of neutrophils will be measured on a SYSMEX automat | Day 7 |
| NETosis markers in Controls before the walking test: reacting monocytes | The percentage of reacting monocytes will be measured on a SYSMEX automat | Day 0 |
| NETosis markers in Controls after the walking test: reacting monocytes | The percentage of reacting monocytes will be measured on a SYSMEX automat | Day 0 |
| NETosis markers in Controls before the walking test: reacting monocytes | The percentage of reacting monocytes will be measured on a SYSMEX automat | Day 7 |
| NETosis markers in Controls after the walking test: reacting monocytes | The percentage of reacting monocytes will be measured on a SYSMEX automat | Day 7 |
| NETosis markers in Controls before the walking test: reacting lymphocytes | The percentage of reacting lymphocytes will be measured on a SYSMEX automat | Day 0 |
| NETosis markers in Controls after the walking test: reacting lymphocytes | The percentage of reacting lymphocytes will be measured on a SYSMEX automat | Day 0 |
| NETosis markers in Patients before the walking test: reacting lymphocytes | The percentage of reacting lymphocytes will be measured on a SYSMEX automat | Day 7 |
| NETosis markers in Patients after the walking test: reacting lymphocytes | The percentage of reacting lymphocytes will be measured on a SYSMEX automat | Day 7 |
| NETosis markers in Controls before the walking test: | The percentage of reacting lymphocytes will be measured on a SYSMEX automat | Day 0 |
| NETosis markers in Controls after the walking test: circulating citrulinated histone H3 | The percentage of circulating citrulinated histone H3 will be measured on a SYSMEX automat | Day 0 |
| NETosis markers in Patients before the walking test: circulating citrulinated histone H3 | The percentage of circulating citrulinated histone H3 will be measured on a SYSMEX automat | Day 7 |
| NETosis markers in Patients after the walking test: circulating citrulinated histone H3 | The percentage of circulating citrulinated histone H3 will be measured on a SYSMEX automat | Day 7 |
| Coagulation factors in Controls before the walking test: fibrinogen | Fibrinogen will be measured in g/L | Day 0 |
| Coagulation factors in Controls before the walking test | Coagulation factors XI, IX, VIII, VII, V, X and II will be measured in International Units | Day 0 |
| Coagulation factors in Controls after the walking test: fibrinogen | Fibrinogen will be measured in g/L | Day 0 |
| Coagulation factors in Controls after the walking test | Coagulation factors XI, IX, VIII, VII, V, X and II will be measured in International Units | Day 0 |
| Coagulation factors in Patients before the walking test: fibrinogen | Fibrinogen will be measured in g/L | Day 7 |
| Coagulation factors in Patients before the walking test | Coagulation factors XI, IX, VIII, VII, V, X and II will be measured in International Units | Day 7 |
| Coagulation factors in Patients after the walking test: fibrinogen | Fibrinogen will be measured in g/L | Day 7 |
| Coagulation factors in Patients after the walking test | Coagulation factors XI, IX, VIII, VII, V, X and II will be measured in International Units | Day 7 |
| Indicators of fibrinoformation in Controls before the walking test: circulating fibrin monomers | Circulating fibrin monomers will be measured in fibrinogen equivalent units | Day 0 |
| Indicators of fibrinoformation in Controls after the walking test: circulating fibrin monomers | Circulating fibrin monomers will be measured in fibrinogen equivalent units | Day 0 |
| Indicators of fibrinoformation in Controls before the walking test: circulating fibrin monomers | Circulating fibrin monomers will be measured in fibrinogen equivalent units | Day 7 |
| Indicators of fibrinoformation in Controls after the walking test: circulating fibrin monomers | Circulating fibrin monomers will be measured in fibrinogen equivalent units | Day 7 |
| Indicators of fibrinoformation in Patients before the walking test: circulating fibrin monomers | Circulating fibrin monomers will be measured in fibrinogen equivalent units | Day 0 |
| Indicators of fibrinoformation in Patients after the walking test: circulating fibrin monomers | Circulating fibrin monomers will be measured in fibrinogen equivalent units | Day 0 |
| Indicators of fibrinoformation in Patients before the walking test: circulating fibrin monomers | Circulating fibrin monomers will be measured in fibrinogen equivalent units | Day 7 |
| Indicators of fibrinoformation in Patients after the walking test: circulating fibrin monomers | Circulating fibrin monomers will be measured in fibrinogen equivalent units | Day 7 |
| Indicators of fibrinoformation in Controls before the walking test: D-dimers | D-dimers will be measured in DDUs | Day 0 |
| Indicators of fibrinoformation in Controls after the walking test: D-dimers | D-dimers will be measured in DDUs | Day 0 |
| Indicators of fibrinoformation in Patients before the walking test: D-dimers | D-dimers will be measured in DDUs | Day 0 |
| Indicators of fibrinoformation in Patients after the walking test: D-dimers | D-dimers will be measured in DDUs | Day 0 |
| Indicators of fibrinoformation in Controls before the walking test: D-dimers | D-dimers will be measured in DDUs | Day 7 |
| Indicators of fibrinoformation in Controls after the walking test: D-dimers | D-dimers will be measured in DDUs | Day 7 |
| Indicators of fibrinoformation in Patients before the walking test: D-dimers | D-dimers will be measured in DDUs | Day 7 |
| Indicators of fibrinoformation in Patients after the walking test: D-dimers | D-dimers will be measured in DDUs | Day 7 |
| Markers of fibrinolysis in Controls before the walking test : Euglobulin lysis time | Euglobulin lysis time will be measured in hours | Day 0 |
| Markers of fibrinolysis in Controls after the walking test : Euglobulin lysis time | Euglobulin lysis time will be measured in hours | Day 0 |
| Markers of fibrinolysis in Patients before the walking test : Euglobulin lysis time | Euglobulin lysis time will be measured in hours | Day 0 |
| Markers of fibrinolysis in Patients after the walking test : Euglobulin lysis time | Euglobulin lysis time will be measured in hours | Day 0 |
| Markers of fibrinolysis in Controls before the walking test : Euglobulin lysis time | Euglobulin lysis time will be measured in hours | Day 7 |
| Markers of fibrinolysis in Controls after the walking test : Euglobulin lysis time | Euglobulin lysis time will be measured in hours | Day 7 |
| Markers of fibrinolysis in Patients before the walking test : Euglobulin lysis time | Euglobulin lysis time will be measured in hours | Day 7 |
| Markers of fibrinolysis in Patients after the walking test : Euglobulin lysis time | Euglobulin lysis time will be measured in hours | Day 7 |
| Markers of Endothelial function in Controls before the walking test: Willebrand factor | Willebrand factor will be measured as a % | Day 0 |
| Markers of Endothelial function in Controls after the walking test: Willebrand factor | Willebrand factor will be measured as a % | Day 0 |
| Markers of Endothelial function in Patients before the walking test: Willebrand factor | Willebrand factor will be measured as a % | Day 0 |
| Markers of Endothelial function in Patients after the walking test: Willebrand factor | Willebrand factor will be measured as a % | Day 0 |
| Markers of Endothelial function in Controls before the walking test: Willebrand factor | Willebrand factor will be measured as a % | Day 7 |
| Markers of Endothelial function in Controls after the walking test: Willebrand factor | Willebrand factor will be measured as a % | Day 7 |
| Markers of Endothelial function in Patients before the walking test: Willebrand factor | Willebrand factor will be measured as a % | Day 7 |
| Markers of Endothelial function in Patients after the walking test: Willebrand factor | Willebrand factor will be measured as a% | Day 7 |
| Markers of Endothelial function in Controls before the walking test: ristocetin cofactor | Ristocetin cofactor will be measured as a % | Day 0 |
| Markers of Endothelial function in Controls after the walking test: ristocetin cofactor | Ristocetin cofactor will be measured as a % | Day 0 |
| Markers of Endothelial function in Patients before the walking test: ristocetin cofactor | Ristocetin cofactor will be measured as a % | Day 0 |
| Markers of Endothelial function in Patients after the walking test: ristocetin cofactor | Ristocetin cofactor will be measured as a % | Day 0 |
| Markers of Endothelial function in Controls before the walking test: ristocetin cofactor | Ristocetin cofactor will be measured as a % | Day 7 |
| Markers of Endothelial function in Controls after the walking test: ristocetin cofactor | Ristocetin cofactor will be measured as a % | Day 7 |
| Markers of Endothelial function in Patients before the walking test: ristocetin cofactor | Ristocetin cofactor will be measured as a % | Day 7 |
| Markers of Endothelial function in Patients after the walking test: ristocetin cofactor | Ristocetin cofactor will be measured as a % | Day 7 |
| Markers of Endothelial function in Controls before the walking test: ADAMTS-13 activity | ADAMTS-13 activity will be measured as a % | Day 0 |
| Markers of Endothelial function in Controls after the walking test: ADAMTS-13 activity | ADAMTS-13 activity will be measured as a % | Day 0 |
| Markers of Endothelial function in Patients before the walking test: ADAMTS-13 activity | ADAMTS-13 activity will be measured as a % | Day 0 |
| Markers of Endothelial function in Patients after the walking test: ADAMTS-13 activity | ADAMTS-13 activity will be measured as a % | Day 0 |
| Markers of Endothelial function in Controls before the walking test: ADAMTS-13 activity | ADAMTS-13 activity will be measured as a % | Day 7 |
| Markers of Endothelial function in Controls after the walking test: ADAMTS-13 activity | ADAMTS-13 activity will be measured as a % | Day 7 |
| Markers of Endothelial function in Patients before the walking test: ADAMTS-13 activity | ADAMTS-13 activity will be measured as a % | Day 7 |
| Markers of Endothelial function in Patients after the walking test: ADAMTS-13 activity | ADAMTS-13 activity will be measured as a % | Day 7 |
| Markers of Endothelial function in Controls before the walking test: soluble thrombomodulin | Soluble thrombomodulin will be measured as a % | Day 0 |
| Markers of Endothelial function in Controls after the walking test: soluble thrombomodulin | Soluble thrombomodulin will be measured as a % | Day 0 |
| Markers of Endothelial function in Patients before the walking test: soluble thrombomodulin | Soluble thrombomodulin will be measured as a % | Day 0 |
| Markers of Endothelial function in Patients after the walking test: soluble thrombomodulin | Soluble thrombomodulin will be measured as a % | Day 0 |
| Markers of Endothelial function in Controls before the walking test: soluble thrombomodulin | Soluble thrombomodulin will be measured as a % | Day 7 |
| Markers of Endothelial function in Controls after the walking test: soluble thrombomodulin | Soluble thrombomodulin will be measured as a % | Day 7 |
| Markers of Endothelial function in Patients before the walking test: soluble thrombomodulin | Soluble thrombomodulin will be measured as a % | Day 7 |
| Markers of Endothelial function in Patients after the walking test: soluble thrombomodulin | Soluble thrombomodulin will be measured as a % | Day 7 |
| Markers of Endothelial function in Controls before the walking test: soluble endothelial protein C receptor | Soluble endothelial protein C receptor will be measured as a % | Day 0 |
| Markers of Endothelial function in Controls after the walking test: soluble endothelial protein C receptor | Soluble endothelial protein C receptor will be measured as a % | Day 0 |
| Markers of Endothelial function in Patients before the walking test: soluble endothelial protein C receptor | Soluble endothelial protein C receptor will be measured as a % | Day 0 |
| Markers of Endothelial function in Patients after the walking test: soluble endothelial protein C receptor | Soluble endothelial protein C receptor will be measured as a % | Day 0 |
| Markers of Endothelial function in Controls before the walking test: soluble endothelial protein C receptor | Soluble endothelial protein C receptor will be measured as a % | Day 7 |
| Markers of Endothelial function in Controls after the walking test: soluble endothelial protein C receptor | Soluble endothelial protein C receptor will be measured as a % | Day 7 |
| Markers of Endothelial function in Patients before the walking test: soluble endothelial protein C receptor | Soluble thrombomodulin will be measured as a % | Day 7 |
| Markers of Endothelial function in Patients after the walking test: soluble endothelial protein C receptor | Soluble thrombomodulin will be measured as a % | Day 7 |
| Body mass index in Controls | Body mass index of controls will be recorded in units of kg/m² | Day 0 |
| Age in Patients | Ages will be recorded in years | Day 0 |
| Sex in Patients | Sex will be recorded as Male/Female/Non-binary | Day 0 |
| Body Mass Index in Patients | Body mass index of controls will be recorded in units of kg/m² | Day 0 |
| D001519 |
| Behavior |